The role of positron emission tomography in skeletal disease

doi:10.1053/snuc.2001.18746

Seminars in Nuclear Medicine

Volume 31, Issue 1, January 2001, Pages 50-61

https://doi.org/10.1053/snuc.2001.18746 Get rights and content

The role of positron emission tomography (PET) in the evaluation and management of skeletal disorders is increasing. A number of reports are available in both benign and malignant disease with a variety of tracers. The bone agent ¹⁸F-fluoride can be used to evaluate bone metastases both qualitatively and, for a number of focal and systemic skeletal disorders, quantitatively. 18-Fluorodeoxyglucose is used as a tumor agent in both primary and metastatic bone and bone marrow malignancies; its use has also been described in the evaluation of infection within the skeleton. A possible role for the use of the hypoxia selective tracer ¹⁸F-fluoromisonidazole in skeletal infection also exists. This article summarizes the current role of PET in the skeleton with regard to these tracers and diseases.

References (62)

BlauM et al.
18 F-fluoride for bone imaging
Sem Nucl Med
(1972)
DuanY et al.
The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur
Bone
(1997)
YamamotoT et al.
Overexpression of facilitative glucose transporter genes in human cancer
Biochem Biophys Res Commun
(1990)
YehSD et al.
Detection of bony metastases of androgen-independent prostate cancer by PET-FDG
Nucl Med Biol
(1996)
CarrR et al.
Detection of lymphoma in bone marrow by whole-body positron emission tomography
Blood
(1998)
CookGJ et al.
Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation
Sem Nucl Med
(1996)
BlauM et al.
A new isotope for bone scanning
J Nucl Med
(1962)
BangS et al.
Topographical distribution of fluoride in iliac bone of a fluoride-treated osteoporotic patient
J Bone Miner Res
(1990)
IshiguroK et al.
Distribution of fluoride in cortical bone of human rib
Calcif Tissue Int
(1993)
NaritaN et al.
Distribution of fluoride concentration in the rat's bone
Calcif Tissue Int
(1990)

HawkinsRA et al.

Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET

J Nucl Med

(1992)

HoegerleS et al.

Combined FDG and [F-18]fluoride whole-body PET: A feasible two-in-one approach to cancer imaging?

Radiology

(1998)

HohCK et al.

Whole body skeletal imaging with [18F]fluoride ion and PET

J Comput Assist Tomogr

(1993)

Petren-MallminM et al.

Skeletal metastases from breast cancer: Uptake of 18F-fluoride measured with positron emission tomography in correlation with CT

Skeletal Radiol

(1998)

SchirrmeisterH et al.

Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography

J Clin Oncol

(1999)

SchirrmeisterH et al.

Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F PET

J Nucl Med

(1999)

MessaC et al.

Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: Correlation with bone histomorphometry

J Clin Endocrinol Metab

(1993)

SchiepersC et al.

Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET

J Nucl Med

(1997)

SchiepersC et al.

Measurement of skeletal flow with positron emission tomography and 18F-fluoride in femoral head osteonecrosis

Arch Orthop Trauma Surg

(1998)

CookGJR et al.

Differences in skeletal kinetics between vertebral and humeral bone measured by 18F-fluoride PET in postmenopausal women

J Bone Miner Res

(2000)

BlakeGM et al.

Quantitative studies of bone with the use of ¹⁸F-fluoride and ^99mTc-methylene diphosphonate

Sem Nucl Med

(2000)

EastellR et al.

Bone formation rate in older normal women: Concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers

J Clin Endocrinol Metab

(1988)

GarneroP et al.

Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis

J Bone Miner Res

(1996)

ArlotM et al.

Impaired osteoblast function in osteoporosis: Comparison between calcium balance and dynamic histomorphometry

Br Med J

(1984)

KellyPJ et al.

Age and menopause-related changes in indices of bone turnover

J Clin Endocrinol Metab

(1989)

BerdingG et al.

Evaluation of the incorporation of bone grafts used in maxillofacial surgery with [18F]fluoride ion and dynamic positron emission tomography

Eur J Nucl Med

(1995)

PiertM et al.

Allogenic bone graft viability after hip revision arthroplasty assessed by dynamic [18F]fluoride ion positron emission tomography

Eur J Nucl Med

(1999)

WoottonR et al.

The clinical measurement of skeletal blood flow

Clin Sci Mol Med

(1976)

FogelmanI et al.

The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease

J Nucl Med

(1978)

EastellR et al.

The value of biochemical markers of bone turnover in osteoporosis

J Rheumatol

(1997)

WarburgO

On the origin of cancer cells

Science

(1954)

Cited by (96)

Translating a radiolabeled imaging agent to the clinic
2022, Advanced Drug Delivery Reviews
Citation Excerpt :
Within a general radiofluorination box, components are often supplied as single use, GMP-compliant cassette components, for instance single use vials, tubing, connectors, and syringes which are often linked together and shipped to radiopharmacies as ‘plug-and-play’ plastic-wrapped fully sterilized components. As mentioned above, it has been found that a very important aspect of radiofluorinated targeting agents is the stability of the radiofluorine-carbon bond, since cleaved radiofluoride is rapidly and specifically taken up in cortical bone, hence the original application of 18F-18 fluoride ion itself for bone imaging [48]. Since many primary cancers metastasize to bone, identification of metastases in the presence of a less-than completely stable radiofluorinated targeting agent presents a significant problem.
Molecular Imaging is entering the most fruitful, exciting period in its history with many new agents under development, and several reaching the clinic in recent years. While it is unusual for just one laboratory to take an agent from initial discovery through to full clinical approval the steps along the way are important to understand for all interested participants even if one is not involved in the entire process. Here, we provide an overview of these processes beginning at discovery and preclinical validation of a new molecular imaging agent and using as an exemplar a low molecular weight disease-specific targeted positron emission tomography (PET) agent. Compared to standard drug development requirements, molecular imaging agents may benefit from a regulatory standpoint from their low mass administered doses, they nonetheless still need to go through a series of well-defined steps before they can be considered for Phase 1 human testing. After outlining the discovery and preclinical validation approaches, we will also discuss the nuances of Phase 1, Phase 2 and Phase 3 studies that may culminate in an FDA general use approval. Finally, some post-approval aspects of novel molecular imaging agents are considered.
Oncology, bone metastases
2022, Nuclear Medicine and Molecular Imaging: Volume 1-4
Metastatic disease is the most common malignancy of the bone and the skeleton is one of the preferential sites for metastases of solid tumor. Osteotropic radiopharmaceuticals are bone seeking agents which target skeleton due to their osteoblastic activity. The most common in clinical use is Sodium-18 fluoride (Na¹⁸F).
¹⁸F-NaF PET/CT plays essential role in initial staging, detection of suspected metastases, suspected progression of osseous metastases or treatment monitoring in many types of cancer, such as prostate, breast and lung cancer. Additionally, the role¹⁸F-NaF PET/CT in the diagnostics of thyroid cancer, renal cell cancer, multiple myeloma and metastatic primary bone tumors is discussed.
Specific oncotropic PET agents are tumor targeting compounds, such as Iodine-124 for metastatic thyroid cancer, and somatostatin analogs (Ga-⁶⁸DOTA-octreotide/octreotate) for neuroendocrine neoplasms. These tracers disclose bone metastases in the malignancies. Multiple tracers for prostate cancer are presented with varying ability to target malignant skeletal disease. Hormone receptor imaging is presented, FES PET is a prime example to demonstrate estrogen receptor positive skeletal disease.
Non-specific oncotropic Agents are important in the detection of skeletal metastases. Actually, the most common PET tracer, F-18 fluorodeoxyglucose (¹⁸F-FDG), plays an important role in the diagnosis of many malignancies. However, the differential diagnosis and sensitivity may sometimes cause problems which should be identified. F-18 (C-11) Choline is associated with lipid synthesis and more sensitive than conventional bone scintigraphy in the diagnosis of bone metastases of prostate cancer. On the contrary, fluorothymidine (¹⁸F-FLT) which targets DNA and cellular proliferation, is not sensitive at all the in the follow-up of skeletal metastases.
This article provides an overview about the diagnostics of bone metastases. Additionally, practical pitfalls are presented as well as new ideas how to improve diagnostics, such as quantitation methods and double-tracer techniques.
Histologic findings and related diagnostic methods in condylar hyperactivity
2021, International Journal of Oral and Maxillofacial Surgery
Citation Excerpt :
The authors suggested that in some of the CH-suspected patients, the affected condyle continues to grow at a normal rate, together with a cessation of growth in the contralateral condylar region. Because PET has a better resolution than SPECT45,46, it could be able to provide a reliable physiologic quantification of metabolism processes in the region of interest45,47,48, thus, it might be a promising tool for identifying active CH. This improved resolution could be explained at least in part, by the different radioisotopes used in SPECT and PET, from which [18F]-fluoride (used in PET), could offer superior biological properties compared with 99mTc-MDP (used in SPECT),45 due to its faster clearance from blood and subsequent lower background radiotracer signal.
Condylar hyperactivity (CH) is a rare condition that entails a progressive deviation and deformation of the mandible. There is no consensus regarding characteristic histopathological features or a standardized diagnostic process; thus, histopathological analysis of the condyle cannot confirm or exclude an active CH after condylectomy is performed. An electronic search was performed in Medline, Embase, Web of Science, LILACS and grey literature up to December 2019. Additionally, a manual search was performed. Risk of bias of the included studies was assessed using the Newcastle–Ottawa Scale and the Institute of Health Economics Quality Appraisal. All analyses were performed independently and in duplicate. Seventeen articles from 660 were included. Six articles were cross-sectional studies and 11 were case series. Almost all the articles (14) described an augmented thickness of the cartilage layer associated with cartilage islands within the subchondral bone in patients affected by CH. Histological findings seem to be mostly related to the age of the sample rather than a characteristic description of CH. No clear association was found between SPECT/scintigram uptake and a specific histological finding. Hence, there is a necessity for the development of specific tools for evaluating and reporting studies where histology is needed for diagnosis confirmation.
Imaging and Management of Prostate Cancer
2020, Seminars in Ultrasound, CT and MRI
Prostate cancer (PCa) is the most common noncutaneous malignancy in men and the second leading cause of cancer related death in the United States. Men with clinical suspicion of PCa undergo tissue sampling and based on features including the Gleason score, Prostate Specific antigen (PSA) levels and clinical tumor (T) stage, patients are risk stratified into 6 major groups based on National Comprehensive Cancer Network (NCCN) guidelines. This forms the basis for deciding imaging and management. Active surveillance is the preferred approach for less aggressive tumors. Surgery or radiation +/− androgen deprivation therapy continue to be the primary treatment options for localized disease. Imaging plays a critical role in the diagnosis, staging and management of PCa. Multiparametric magnetic resonance imaging (mpMRI) is currently the imaging modality of choice for locoregional staging. MRI, computed tomography and bone scan remain the preferred modalities for evaluation of nodal, soft tissue, and bone metastases, respectively. Advanced positron emission tomography imaging using novel radiotracers are being developed but are not yet integrated in the diagnostic guidelines for initial staging. In this review, we will discuss the imaging and treatment algorithms based on the NCCN risk groups, describe the utility of individual modalities, review Prosate Imaging and Reporting and Data System (PIRADS) version 2.1 for the reporting of mpMRI of the prostate.
The role of 18F-NaF PET/CT in metastatic bone disease
2015, Journal of Bone Oncology
To investigate the role of 18F–NaF PET/CT and compare it with 99m Tc-MDP whole body bone scintigraphy and 18F-FDG PET/CT in detecting the extent of metastatic bone disease and to present our first experience with 18F–NaF PET/CT in our country.
A total of 37 histopathologically proven cancer patients (22 male, 15 female) with bone metastasis detected on Tc-99m MDP whole body bone scan were prospectively enrolled Cebeci, following ethics committee approval. 18F–NaF PET/CT was performed to the participants in Ankara University Medical Faculty Nuclear Medicine Department for evaluation of symptomatic skeletal sites which were negative on Tc-99m MDP whole body bone scan. A lesion based comparison was made between 18F–NaF PET/CT and Tc-99m MDP whole body bone scan for each patient and between 18F–NaF PET/CT and 18F-FDG PET/CT in 12/37 patients.
The number of lesions demonstrated by 99m Tc-MDP bone scan and 18F–NaF PET/CT was equal in 4/37 (%11) of the cases. 18F–NaF PET/CT showed a greater number of pathological foci in 89% of participants. 18F–NaF PET/CT was able to show both lytic and blastic lesions and small lesions were better visualized due to the advantage of sectional imaging with much better resolution and higher target/background ratio. 18F–NaF PET/CT demonstrated a greater number of metastases in 10/12 (83%) of the patients when compared to 18F-FDG PET/CT. In the other two patients, bone metastasis could be demonstrated only by 18F–NaF PET/CT. The uptake of 18F-FDG was variable in blastic lesions and cranial bone involvement was missed by 18F-FDG PET/CT in some cases due to physiological brain metabolism.
Although further prospective clinical studies in specific cancer populations are indicated to set the place of 18F–NaF PET/CT in diagnostic scheme, the results of this pilot study from our country support the superiority of 18F–NaF PET/CT in investigation of bone metastasis over 99mTc-MDP bone scan and 18F-FDG PET/CT in various malignancies. 18F–NaF PET/CT is coming forward as a single step bone seeking study, considering all the advantages, but especially potential of detecting occult metastases and reliably directing patient management.
Pitfalls and limitations of radionuclide planar and hybrid bone imaging
2015, Seminars in Nuclear Medicine
Citation Excerpt :
This is because increased 18F-fluoride uptake is generally seen in lytic metastases where a minimal osteoblastic response owing to an osteolytic lesion may not be detected on a planar 99mTc-MDP bone scan.78 However, similar to 99mTc-MDP, 18F-fluoride is not a tumor-specific agent and therefore has limited ability in differentiating benign from malignant pathology.79 In addition, benign lesions that may not show increased 99mTc-MDP uptake may often demonstrate increased 18F-fluoride uptake owing to high sensitivity in detecting an osteoblastic response.
The radionuclide ^99mTc-MDP bone scan is one of the most commonly performed nuclear medicine studies and helps in the diagnosis of different pathologies relating to the musculoskeletal system. With its increasing utility in clinical practice, it becomes more important to be aware of various limitations of this imaging modality to avoid false interpretation. It is necessary to be able to recognize various technical, radiopharmaceutical, and patient-related artifacts that can occur while carrying out a bone scan. Furthermore, several normal variations of tracer uptake may mimic pathology and should be interpreted cautiously. There is an important limitation of a bone scan in metastatic disease evaluation as the inherent mechanism of tracer uptake is not specific for tumor but primarily relies on an osteoblastic response. Thus, it is crucial to keep in mind uptake in benign lesions, which can resemble malignant pathologies. The utility of a planar bone scan in benign orthopedic diseases, especially at sites with complex anatomy, is limited owing to lack of precise anatomical information. SPECT/CT has been significantly helpful in these cases. With wider use of PET/CT and reintroduction of the ¹⁸F-fluoride bone scan, increasing knowledge of potential pitfalls on an ¹⁸F-fluoride bone scan and ¹⁸F-FDG-PET/CT will help in improving the accuracy of clinical reports.

View all citing articles on Scopus

View full text

The role of positron emission tomography in skeletal disease

Sem Nucl Med

Bone

Biochem Biophys Res Commun

Nucl Med Biol

Blood

Sem Nucl Med

A new isotope for bone scanning

J Nucl Med

Topographical distribution of fluoride in iliac bone of a fluoride-treated osteoporotic patient

J Bone Miner Res

Distribution of fluoride in cortical bone of human rib

Calcif Tissue Int

Distribution of fluoride concentration in the rat's bone

Calcif Tissue Int

Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET

J Nucl Med

Combined FDG and [F-18]fluoride whole-body PET: A feasible two-in-one approach to cancer imaging?

Radiology

Whole body skeletal imaging with [18F]fluoride ion and PET

J Comput Assist Tomogr

Skeletal metastases from breast cancer: Uptake of 18F-fluoride measured with positron emission tomography in correlation with CT

Skeletal Radiol

Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography

J Clin Oncol

Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F PET

J Nucl Med

Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: Correlation with bone histomorphometry

J Clin Endocrinol Metab

Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET

J Nucl Med

Measurement of skeletal flow with positron emission tomography and 18F-fluoride in femoral head osteonecrosis

Arch Orthop Trauma Surg

Differences in skeletal kinetics between vertebral and humeral bone measured by 18F-fluoride PET in postmenopausal women

J Bone Miner Res

Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate

Sem Nucl Med

Bone formation rate in older normal women: Concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers

J Clin Endocrinol Metab

Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis

J Bone Miner Res

Impaired osteoblast function in osteoporosis: Comparison between calcium balance and dynamic histomorphometry

Br Med J

Age and menopause-related changes in indices of bone turnover

J Clin Endocrinol Metab

Evaluation of the incorporation of bone grafts used in maxillofacial surgery with [18F]fluoride ion and dynamic positron emission tomography

Eur J Nucl Med

Allogenic bone graft viability after hip revision arthroplasty assessed by dynamic [18F]fluoride ion positron emission tomography

Eur J Nucl Med

The clinical measurement of skeletal blood flow

Clin Sci Mol Med

The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease

J Nucl Med

The value of biochemical markers of bone turnover in osteoporosis

J Rheumatol

On the origin of cancer cells

Science

Quantitative studies of bone with the use of ¹⁸F-fluoride and ^99mTc-methylene diphosphonate